Are drotaverine, hyoscine (hyoscine butyl‑bromide), and valethamate effective and safe for improving an unfavorable Bishop score?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Drotaverine, Hyoscine, and Valethamate for Improving Bishop Score

Direct Answer

None of these antispasmodic agents (drotaverine, hyoscine butyl-bromide, or valethamate) are recommended for improving an unfavorable Bishop score, as they do not perform cervical ripening—instead, use dinoprostone or mechanical methods (Foley catheter) for cervical ripening when the Bishop score is <5. 1, 2


Understanding the Clinical Context

What These Drugs Actually Do

  • Antispasmodics (drotaverine, hyoscine, valethamate) reduce smooth muscle spasm and may accelerate cervical dilation during active labor, but they do not ripen an unfavorable cervix before labor begins. 3

  • The Bishop score <5 identifies an unfavorable cervix that requires cervical ripening before oxytocin or active labor management can be effective. 1, 4

  • Cervical ripening and labor augmentation are fundamentally different processes: ripening changes cervical structure (softening, effacement) while augmentation enhances uterine contractions during established labor. 1


Evidence on Antispasmodics in Labor

Efficacy During Active Labor (Not Cervical Ripening)

  • A 2012 Cochrane review found that antispasmodics (including valethamate, hyoscine, and drotaverine) reduced first stage labor duration by 66 minutes and increased cervical dilation rate by 0.55 cm/hour, but this was in women already in established labor, not for cervical ripening. 3

  • The evidence quality was low due to poor study design, significant heterogeneity, and inconsistent reporting of adverse events. 3

Comparative Studies Show Conflicting Results

  • A 2001 trial found drotaverine superior to valethamate (injection-to-delivery interval 194 vs 221 minutes), with fewer side effects, but both groups were already at 4 cm dilation in active labor. 5

  • A 2010 study confirmed drotaverine reduced injection-delivery time to 183 minutes versus 207 minutes for valethamate and 245 minutes for placebo, again in women already in active labor at 4 cm. 6

  • However, a 2008 trial found no significant difference between drotaverine and hyoscine versus controls for labor augmentation, with mean active phase durations of 4.5,3.9, and 3.6 hours respectively (not statistically significant). 7

  • A 2020 meta-analysis of hyoscine showed it reduced active labor phase by 84 minutes overall, but with 99% heterogeneity between studies, limiting confidence in the findings. 8


Correct Approach to Unfavorable Bishop Score

Step 1: Assess Cervical Favorability

  • Measure the Bishop score before induction; a score <5 mandates cervical ripening before oxytocin can work. 1, 4

  • A Bishop score ≥5 permits immediate oxytocin and amniotomy without prior ripening. 1

Step 2: Choose Appropriate Cervical Ripening Method

First-Line: Dinoprostone (Prostaglandin E₂)

  • Dinoprostone 10 mg vaginal insert (releasing 0.3 mg/hour) is indicated for cervical ripening in women with Bishop score <5, removed after 12 hours maximum or onset of active labor. 2

  • Wait at least 30 minutes after removing dinoprostone before starting oxytocin. 1

  • Continuous fetal heart rate and uterine activity monitoring are mandatory throughout dinoprostone use. 2

Alternative: Oral Misoprostol

  • Oral misoprostol 20-25 µg every 2-6 hours results in fewer cesarean sections (RR 0.84) and costs significantly less than dinoprostone. 1

  • Misoprostol is absolutely contraindicated in women with prior cesarean delivery due to 13% uterine rupture risk. 1

Alternative: Mechanical Methods (Foley Catheter)

  • Mechanical cervical ripening is preferred over prostaglandins in women with prior cesarean delivery or active cardiovascular disease. 1, 2

  • Administer pre-procedure NSAID (naproxen 500-550 mg or ibuprofen 800 mg) 1-2 hours before Foley insertion to reduce discomfort. 1


Critical Contraindications to Dinoprostone

  • Active cardiovascular disease is an absolute contraindication to dinoprostone due to marked blood pressure changes, potential coronary vasospasm, and arrhythmia risk. 2

  • Cyanotic heart disease contraindicates dinoprostone because it reduces systemic vascular resistance and worsens hemodynamics. 2

  • In these patients, use mechanical methods (Foley catheter) exclusively for cervical ripening. 2


When to Consider Antispasmodics (After Ripening)

  • Once cervical ripening is complete and active labor is established (typically ≥4 cm dilation with regular contractions), antispasmodics may be considered as adjuncts to accelerate labor, though evidence is mixed. 3, 5, 6

  • Drotaverine appears to have fewer side effects than valethamate (which causes maternal tachycardia, flushing, dry mouth), but neither drug addresses the fundamental problem of an unfavorable cervix. 5, 6

  • Hyoscine evidence is highly heterogeneous and unreliable for clinical decision-making. 8


Definition of Failed Induction

  • Allow at least 12 hours after completing cervical ripening, membrane rupture, and oxytocin use before declaring "failed induction" and proceeding to cesarean delivery. 1

  • Nulliparous women require longer induction times (often 24+ hours total) while multiparous women progress faster with dilation rates ≥1.5 cm/hour. 1


Common Pitfalls to Avoid

  • Do not use antispasmodics as a substitute for proper cervical ripening when Bishop score is <5—they will not soften or efface the cervix. 1, 3

  • Do not initiate oxytocin when Bishop score is <5 without first performing cervical ripening; oxytocin alone is ineffective in this setting. 1

  • Do not use dinoprostone in patients with active cardiovascular disease; switch to mechanical methods immediately. 2

  • Do not declare failed induction before the mandatory 12-hour observation period after ripening, membrane rupture, and adequate oxytocin titration. 1

  • Do not use misoprostol in women with prior cesarean section due to high uterine rupture risk. 1

References

Guideline

Management of Labor Induction and Amniotomy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Dinoprostone for Cervical Ripening: Contraindications and Management in Cardiovascular Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Antispasmodics for labour.

The Cochrane database of systematic reviews, 2012

Guideline

Cervical Readiness Assessment for Labor Induction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Drotaverine hydrochloride vs. valethamate bromide in acceleration of labor.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2001

Research

Drotaverine hydrochloride versus hyoscine-N-butylbromide in augmentation of labor.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2008

Related Questions

What is the recommended dosing regimen of Epidosin (valethamate bromide) for a woman in active first‑stage labour who has no severe hepatic or renal disease, no hypersensitivity to anticholinergic agents, and no evidence of uterine rupture or fetal distress?
In a woman in active first‑stage labour without severe hepatic or renal disease, hypersensitivity, uterine rupture, or fetal distress, can drotaverine and Epidosin (valethamate bromide) be administered together intramuscularly?
What is the mechanism of action of drotaverine, hyoscine butylbromide (scopolamine butylbromide), and valethamate bromide when administered after active labor has begun?
What is the preferred treatment for first trimester pregnant women with abortus incipiens (threatened abortion), comparing drotaverine and papaverine to buscolysine?
What are the maternal and fetal side effects of hyoscine butylbromide and scopolamine when used in pregnant women during active labor?
What are the common and serious adverse effects of Trileptal (oxcarbazepine) and how should they be monitored?
In an adult without known chronic liver disease, what does an alkaline phosphatase of 319 U/L, alanine aminotransferase of 257 U/L, and aspartate aminotransferase of 92 U/L indicate and how should it be evaluated?
What is the recommended treatment for Campylobacter-induced diarrhea?
What is the appropriate work‑up for a postpartum woman with severe hemorrhage, failure to lactate, amenorrhea, and signs of hypothyroidism or adrenal insufficiency suggestive of Sheehan syndrome?
What are acrochordons (skin tags) and what are the recommended treatment options for removal?
What are the active medications in Trelegy Ellipta, its approved dosage strength, dosing frequency, and approved indications for chronic obstructive pulmonary disease and asthma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.